Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Liminal BioSciences Inc. (LMNL)

5.32   0.31 (6.19%) 02-03 15:20
Open: 5.17 Pre. Close: 5.01
High: 5.78 Low: 5.01
Volume: 75,016 Market Cap: 165(M)

Technical analysis

as of: 2023-02-03 3:18:46 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 6.75     One year: 7.88
Support: Support1: 2.39    Support2: 0.31
Resistance: Resistance1: 5.78    Resistance2: 6.75
Pivot: 1.37
Moving Average: MA(5): 3.33     MA(20): 1.11
MA(100): 0.58     MA(250): 0.62
MACD: MACD(12,26): 0.9     Signal(9): 0.3
Stochastic oscillator: %K(14,3): 94.7     %D(3): 88.8
RSI: RSI(14): 93.6
52-week: High: 5.78  Low: 0.31
Average Vol(K): 3-Month: 33 (K)  10-Days: 58 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ LMNL ] has closed above the upper band by 3.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 2662.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.42 - 5.45 5.45 - 5.47
Low: 4.95 - 4.98 4.98 - 5
Close: 4.97 - 5.01 5.01 - 5.05

Company Description

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Headline News

Thu, 02 Feb 2023
Liminal collaborates with Metamask Institutional to boost Institutional Crypto Adoption - EIN News

Thu, 26 Jan 2023
Liminal BioSciences (NASDAQ:LMNL) announces 10-for-1 reverse ... - Seeking Alpha

Thu, 26 Jan 2023
Liminal BioSciences Announces Reverse Stock Split - Liminal Biosciences (NASDAQ:LMNL) - Benzinga

Thu, 19 Jan 2023
Liminal BioSciences to Present at BIO CEO & Investor Conference ... - PR Newswire

Fri, 06 Jan 2023
Liminal BioSciences Announces Priorities For 2023 - Yahoo Finance

Wed, 04 Jan 2023
LMNL office tops brick clad house with fragmented thatched roof in ... - Designboom

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 3 (M)
Shares Float 0 (M)
% Held by Insiders 3.104e+007 (%)
% Held by Institutions 9.22e+006 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.77e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.27
Profit Margin (%) 8
Operating Margin (%) 610.7
Return on Assets (ttm) -7
Return on Equity (ttm) 441.5
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0.18
Sales Per Share -0.01
EBITDA (p.s.) 0
Qtrly Earnings Growth -4.084e+007
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value -20.95
Price to Sales -470571
Price to Cash Flow 0

Stock Dividends

Dividend 89950
Forward Dividend 337800
Dividend Yield 1626580%
Dividend Pay Date 2019-07-04
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.